Status:
WITHDRAWN
Steroids for Early Treatment of Radiation Retinopathy
Lead Sponsor:
The Cleveland Clinic
Conditions:
Radiation Retinopathy
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
Radiation retinopathy is a known complication of ocular radiation therapy. To date there is no known effective treatment. In addition to their anti-vascular endothelial growth factor (VEGF) properties...
Detailed Description
The purpose of the project is threefold: 1. To study the natural history of radiation retinopathy using advanced imaging techniques. A combination of macular OCT to evaluate for edema, OCT angiograph...
Eligibility Criteria
Inclusion
- Primary uveal melanoma
- Primary treatment with plaque brachytherapy
- Baseline visual acuity 20/200 or better
- Posterior tumor margin \>1.50 mm from the center of the macula
- Posterior tumor margin \> 1.50 mm from the closest disc margin
- Calculated total dose to center of the macula \>40 Gy
Exclusion
- Iris melanoma
- Opaque media
- less than 21 years of age
- Inability to give consent
- Positive pregnancy test
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03238157
Start Date
February 1 2022
End Date
September 1 2022
Last Update
August 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cole Eye Instiute
Cleveland, Ohio, United States, 44195